NEW YORK (360Dx) – A blood test being prepared for launch around the end of this year could enable early diagnosis of aggressive prostate cancer and reduce the number of men undergoing painful biopsies and unnecessary surgeries, according to its developers.

Earlier this year, they formed a company called Nanostics to prepare their technology for a commercial launch.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.